Astellas, Pfizer bag Xtandi FDA approval for non-metastatic CRPC
In a significant development, Astellas Pharma and Pfizer have announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of their cancer ... Read More
Pfizer faces setback as Reckitt Benckiser and GSK withdraw from $20bn consumer health deal
Pfizer's $20 Billion Sale Stalls: In a significant turn of events in the pharmaceutical industry, both Reckitt Benckiser and GlaxoSmithKline (GSK) have decided to withdraw ... Read More
Biogen strikes $600m deal with Pfizer for promising schizophrenia drug
Biogen, a leading US biotechnology firm, has reached a significant agreement to acquire Pfizer's neurology drug candidate, PF-04958242, which is being developed to address cognitive ... Read More
Pfizer exits Chinese generic drugs JV, Hisun-Pfizer Pharmaceuticals
In a significant shift within the pharmaceutical industry, Pfizer Inc. has announced its decision to exit the Hisun-Pfizer Pharmaceuticals joint venture by divesting its 49% ... Read More
FDA clears Servier and Pfizer for clinical development of UCART19 for acute lymphoblastic leukemia
Servier and Pfizer Inc. have received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to proceed with the clinical development ... Read More
Pfizer’s inotuzumab ozogamicin gains FDA priority review in acute lymphoblastic leukemia
Pfizer Inc. has received a priority review designation from the U.S. Food and Drug Administration (FDA) for its innovative blood cancer drug, inotuzumab ozogamicin. This ... Read More